do_not_disturb_altRecruitment Complete

Amyloid Cardiomyopathy

Bayer Identifier:
AG10-202
ClinicalTrials.gov Identifier:
NCT03536767
EudraCT Number:
Not Available
EU CT Number:
Not Available
An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201

Trial purpose

Key Participants Requirements

Sex

N/A

Age

N/A

    Trial summary

    Enrollment Goal
    N/A
    Trial Dates
    August 2018 - July 2027
    Phase
    Phase 2
    Could I Receive a placebo
    N/A
    Products
    Acoramidis (BAY3684938)
    Accepts Healthy Volunteer
    N/A

    Trial design

    An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201
    Trial Type
    Interventional
    Intervention Type
    N/A
    Trial Purpose
    Treatment
    Allocation
    N/A
    Blinding
    N/A
    Assignment
    N/A
    Trial Arms
    N/A